An Overview of New Biologics for Migraine Prophylaxis

Philip Harvey, PharmD/MBA Candidate 2020; Pooja Shah, PharmD/MBA Candidate 2020; Scott Shipley, PharmD, BCPS


US Pharmacist. 2020;45(1):21-24. 

In This Article


CGRP antagonists appear to significantly improve treatment outcomes in patients who experience episodic or chronic migraines.[19] Previously, there were no medications specifically designed for the prophylactic treatment of migraines until the release of these three new monoclonal antibodies. These agents have ushered a new era of migraine therapy. Because this new class of injectable monoclonal antibodies is directed against a new system and these agents are proven efficacious, pharmacists will have an opportunity to not only educate their patients on proper care, but also inform providers on appropriate use. Patients may experience minimal side effects from a very well tolerated therapeutic regimen that could begin improving their headache days within the first month. Although these CGRP antagonists have been shown to prevent and reduce headache days in clinical trials, they may not work for everyone, and not all patients will benefit. Considerations should be made according to the patient's health and comorbidities. The patient should discuss with his or her physician whether a CGRP antagonist is the best therapy choice compared with other treatment options for migraine.